U.S. Markets closed
  • S&P Futures

    3,296.75
    -2.50 (-0.08%)
     
  • Dow Futures

    27,212.00
    +69.00 (+0.25%)
     
  • Nasdaq Futures

    11,087.50
    -62.00 (-0.56%)
     
  • Russell 2000 Futures

    1,487.80
    -1.00 (-0.07%)
     
  • Crude Oil

    39.55
    -0.05 (-0.13%)
     
  • Gold

    1,905.70
    -1.90 (-0.10%)
     
  • Silver

    24.42
    -0.10 (-0.40%)
     
  • EUR/USD

    1.1686
    -0.0023 (-0.1987%)
     
  • 10-Yr Bond

    0.6640
    -0.0070 (-1.04%)
     
  • Vix

    26.86
    -0.92 (-3.31%)
     
  • GBP/USD

    1.2723
    -0.0014 (-0.1069%)
     
  • BTC-USD

    10,525.15
    -16.61 (-0.16%)
     
  • CMC Crypto 200

    223.53
    +9.77 (+4.57%)
     
  • FTSE 100

    5,829.46
    +25.17 (+0.43%)
     
  • Nikkei 225

    23,236.89
    -123.41 (-0.53%)
     

Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020




HOLON, Israel, July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2020 financial results on Thursday, July 30, 2020 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-888-407-2553 from the U.S.,
or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972-(3)-765-8124

Investor Relations contact:
Bob Yedid
LifeSci Advisors, LLC
Email: bob@lifesciadvisors.com
Tel: +1-(646)-597-6989

Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications
Email: jo@lifescicomms.com
Tel: +1-(646)-751-4361

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2020-results-on-thursday-july-30-2020-301094676.html

SOURCE Compugen Ltd.